JP7489989B2 - （ｓ）－４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルを含む医薬組成物及びその使用方法 - Google Patents

（ｓ）－４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルを含む医薬組成物及びその使用方法 Download PDF

Info

Publication number
JP7489989B2
JP7489989B2 JP2021539972A JP2021539972A JP7489989B2 JP 7489989 B2 JP7489989 B2 JP 7489989B2 JP 2021539972 A JP2021539972 A JP 2021539972A JP 2021539972 A JP2021539972 A JP 2021539972A JP 7489989 B2 JP7489989 B2 JP 7489989B2
Authority
JP
Japan
Prior art keywords
weight
amount
compound
pharmaceutical composition
starch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021539972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516989A (ja
JP2022516989A5 (https=
Inventor
アグラワル アンジャリ
ジェイ． シェン ミン
バブ カーキ シャム
ガンワンス スール プラジュワル
ヴィスキー ドーラ
シェ ルイミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2022516989A publication Critical patent/JP2022516989A/ja
Publication of JP2022516989A5 publication Critical patent/JP2022516989A5/ja
Application granted granted Critical
Publication of JP7489989B2 publication Critical patent/JP7489989B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021539972A 2019-01-09 2020-01-08 （ｓ）－４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルを含む医薬組成物及びその使用方法 Active JP7489989B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962790229P 2019-01-09 2019-01-09
US62/790,229 2019-01-09
PCT/US2020/012649 WO2020146441A1 (en) 2019-01-09 2020-01-08 Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same

Publications (3)

Publication Number Publication Date
JP2022516989A JP2022516989A (ja) 2022-03-03
JP2022516989A5 JP2022516989A5 (https=) 2023-01-24
JP7489989B2 true JP7489989B2 (ja) 2024-05-24

Family

ID=69500831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539972A Active JP7489989B2 (ja) 2019-01-09 2020-01-08 （ｓ）－４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルを含む医薬組成物及びその使用方法

Country Status (12)

Country Link
US (3) US11779580B2 (https=)
EP (1) EP3908254A1 (https=)
JP (1) JP7489989B2 (https=)
KR (1) KR20210113290A (https=)
CN (2) CN113597301A (https=)
AU (1) AU2020206692B2 (https=)
CA (1) CA3126067A1 (https=)
EA (1) EA202191904A1 (https=)
IL (1) IL284665A (https=)
MX (1) MX2021008321A (https=)
SG (1) SG11202107438WA (https=)
WO (1) WO2020146441A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4178548T3 (da) 2020-07-07 2024-08-19 Celgene Corp Farmaceutiske sammensætninger omfattende (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUORBENZONITRIL
KR20240013793A (ko) 2021-05-27 2024-01-30 셀진 코포레이션 조합 요법을 사용하는 다발성 골수종의 치료 방법
WO2025240252A1 (en) * 2024-05-13 2025-11-20 Beta Pharma, Inc. Estrogen receptor degraders as treatments for breast cancer

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503032A (ja) 2002-09-10 2006-01-26 ファーマシア イタリア エス．ピー．エー インドリノン化合物を含む固形製剤
JP2013519675A (ja) 2010-02-11 2013-05-30 セルジーン コーポレイション アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法
WO2013087516A2 (en) 2011-12-13 2013-06-20 Unilever Plc Oil-in-water cosmetic compositions
WO2014191806A2 (en) 2013-05-02 2014-12-04 Effrx Pharmaceuticals Sa Effervescent formulations that deliver particles which float in the stomach
JP2016532657A (ja) 2013-10-08 2016-10-20 セルジーン コーポレイション （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの製剤
JP2021525362A (ja) 2018-05-23 2021-09-24 セルジーン コーポレイション 多発性骨髄腫を治療すること及び４−（４−（４−（（（２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン−４−イル）オキシ）メチル）ベンジル）ピペラジン−１−イル）−３−フルオロベンゾニトリルのバイオマーカーの使用
JP2022516974A (ja) 2019-01-09 2022-03-03 セルジーン コーポレイション 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法
JP2022518175A (ja) 2019-01-09 2022-03-14 セルジーン コーポレイション （ｓ）－４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルを含む固体形態及びその塩、ならびにそれらを含む組成物及びその使用方法
JP7258009B2 (ja) 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
JP2023116613A (ja) 2018-05-23 2023-08-22 セルジーン コーポレイション 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503032A (ja) 2002-09-10 2006-01-26 ファーマシア イタリア エス．ピー．エー インドリノン化合物を含む固形製剤
JP2013519675A (ja) 2010-02-11 2013-05-30 セルジーン コーポレイション アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法
WO2013087516A2 (en) 2011-12-13 2013-06-20 Unilever Plc Oil-in-water cosmetic compositions
WO2014191806A2 (en) 2013-05-02 2014-12-04 Effrx Pharmaceuticals Sa Effervescent formulations that deliver particles which float in the stomach
JP2016532657A (ja) 2013-10-08 2016-10-20 セルジーン コーポレイション （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの製剤
JP7258009B2 (ja) 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
JP2021525362A (ja) 2018-05-23 2021-09-24 セルジーン コーポレイション 多発性骨髄腫を治療すること及び４−（４−（４−（（（２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン−４−イル）オキシ）メチル）ベンジル）ピペラジン−１−イル）−３−フルオロベンゾニトリルのバイオマーカーの使用
JP2023116613A (ja) 2018-05-23 2023-08-22 セルジーン コーポレイション 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体
JP2022516974A (ja) 2019-01-09 2022-03-03 セルジーン コーポレイション 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法
JP2022518175A (ja) 2019-01-09 2022-03-14 セルジーン コーポレイション （ｓ）－４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルを含む固体形態及びその塩、ならびにそれらを含む組成物及びその使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Australian Journal of Pharmacy，2017年，Vol.98，pp.78-83

Also Published As

Publication number Publication date
WO2020146441A1 (en) 2020-07-16
AU2020206692A1 (en) 2021-07-29
AU2020206692B2 (en) 2025-03-27
CN114409630B (zh) 2024-04-02
MX2021008321A (es) 2021-10-13
CN114409630A (zh) 2022-04-29
US12064427B2 (en) 2024-08-20
JP2022516989A (ja) 2022-03-03
US11779580B2 (en) 2023-10-10
KR20210113290A (ko) 2021-09-15
CA3126067A1 (en) 2020-07-16
BR112021013383A2 (pt) 2021-09-14
EA202191904A1 (ru) 2021-10-04
US20240358697A1 (en) 2024-10-31
IL284665A (en) 2021-08-31
SG11202107438WA (en) 2021-08-30
CN113597301A (zh) 2021-11-02
EP3908254A1 (en) 2021-11-17
US20200215061A1 (en) 2020-07-09
US20240066026A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
JP7258009B2 (ja) 抗増殖化合物及びその使用方法
US12064427B2 (en) Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
US12391672B2 (en) Solid forms comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
JP2022516974A (ja) 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法
US20260034122A1 (en) Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
EA046729B1 (ru) Фармацевтические композиции, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил, и способы их применения
BR112021013383B1 (pt) Composições farmacêuticas compreendendo (s)-4-(4-(4-(((2-(2,6- dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin1-il)-3-fluorobenzonitrila, processo para preparar as mesmas e uso das referidas composições
HK40063850B (en) Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
HK40063850A (en) Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240416

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240514

R150 Certificate of patent or registration of utility model

Ref document number: 7489989

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150